Skip to content

Study · Observational study · n = 117 · 2008

3 results

Prevention of ovarian function damage by a GnRH analogue during chemotherapy in Hodgkin lymphoma patients.

Huser M, Crha I, Ventruba P, Hudecek R, Zakova J, Smardova L, Kral Z, Jarkovsky J

Human reproduction (Oxford, England)7 Feb 2008Cited by 32 (Europe PMC)

PMID18258763 (opens in a new tab)DOI10.1093/humrep/den005 (opens in a new tab)PepBankPUB-18258763
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In women with Hodgkin lymphoma, triptorelin during chemotherapy was linked to less ovarian failure at 6 months than historical chemotherapy alone.

    In plain wordsIn women with Hodgkin lymphoma, triptorelin during chemotherapy was linked to less ovarian failure than historical chemotherapy alone at follow-up.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreasePremature ovarian failure at 6 months
    Study

    n = 117

    Comparator
    Historical chemotherapy cohort without GnRH analogue
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Premature ovarian failure
    37.5%
    triptorelin at 6 months
    Premature ovarian failure
    73.3%
    historical controls at 6 months
    P value
    < 0.001 none
    POF, triptorelin vs historical controls

    Source sentences

    Summary
    In study group with GnRH analogue administration during CHT, there was significantly (P < 0.001) fewer cases with POF 6 and 12 month after the end of CHT (37.5% and 20.8%, respectively) than in control group (73.3% and 71.1%, respectively).
    2 context sentences
    Summary · context
    Study group consists of 72 patients in fertile age (18-35 years) with HL diagnosis treated in 2004-2005 by curative CHT together with GnRH analogue (Triptorelin) administration according to a standardized protocol.
    Summary · context
    The number of women with POF after CHT in study group was compared with control group (n = 45, age 18-35 years) of patients treated in 2002-2003 according to the same protocol but without protective GnRH analogue application.
  2. 02HumanObservational studyEfficacy outcome

    In women with Hodgkin lymphoma, triptorelin during chemotherapy was linked to less ovarian failure at 12 months than historical chemotherapy alone.

    In plain wordsIn women with Hodgkin lymphoma, triptorelin during chemotherapy was linked to less ovarian failure than historical chemotherapy alone at later follow-up.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreasePremature ovarian failure at 12 months
    Study

    n = 117

    Comparator
    Historical chemotherapy cohort without GnRH analogue
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Premature ovarian failure
    20.8%
    triptorelin at 12 months
    Premature ovarian failure
    71.1%
    historical controls at 12 months
    P value
    < 0.001 none
    POF, triptorelin vs historical controls

    Source sentences

    Summary
    In study group with GnRH analogue administration during CHT, there was significantly (P < 0.001) fewer cases with POF 6 and 12 month after the end of CHT (37.5% and 20.8%, respectively) than in control group (73.3% and 71.1%, respectively).
    2 context sentences
    Summary · context
    Study group consists of 72 patients in fertile age (18-35 years) with HL diagnosis treated in 2004-2005 by curative CHT together with GnRH analogue (Triptorelin) administration according to a standardized protocol.
    Summary · context
    The number of women with POF after CHT in study group was compared with control group (n = 45, age 18-35 years) of patients treated in 2002-2003 according to the same protocol but without protective GnRH analogue application.
  3. 03HumanObservational studyEfficacy outcome

    In women with Hodgkin lymphoma, ovarian failure differed between triptorelin and historical control groups only with less aggressive chemotherapy protocols.

    In plain wordsIn women with Hodgkin lymphoma, ovarian failure differed between triptorelin and historical controls only with less aggressive chemotherapy.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    MixedOvarian failure by chemotherapy cytotoxicity
    Study

    n: not reported in source

    Comparator
    Historical chemotherapy cohort without GnRH analogue
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Comparative analysis depending on cytotoxicity of CHT regimen used showed significant differences in percentage of patient with acquired POF between study and control group only in less aggressive CHT protocols.
    2 context sentences
    Summary · context
    Study group consists of 72 patients in fertile age (18-35 years) with HL diagnosis treated in 2004-2005 by curative CHT together with GnRH analogue (Triptorelin) administration according to a standardized protocol.
    Summary · context
    The number of women with POF after CHT in study group was compared with control group (n = 45, age 18-35 years) of patients treated in 2002-2003 according to the same protocol but without protective GnRH analogue application.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedNot applicableNCT01764230

Prevention of Ovarian Function Damage by a GnRH Analogue During Chemotherapy in Hodgkin Lymphoma Patients

Masaryk Universityn = 72Jan 2004 to Jan 2008

Hodgkin Lymphoma · Hodgkin Disease

Trial pageClinicalTrials.govUpdated 9 Jan 2013

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.